Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
9 May 2024
|
|
N 10:45 | FUTIBATINIB 2 changes history +1,225 [Hafiza Amna Qadeer (2×)] | |||
|
|
10:45 (cur | prev) −12 Hafiza Amna Qadeer talk contribs | ||||
| N |
|
10:37 (cur | prev) +1,237 Hafiza Amna Qadeer talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...") | |||
| N 04:57 | Sotagliflozin diffhist +418 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}") | ||||
8 May 2024
| 21:38 | Template:KDRG diffhist +174 Kosar Doraghi talk contribs | ||||
|
|
N 21:38 | EXXUA 2 changes history +11,572 [Kosar Doraghi (2×)] | |||
|
|
21:38 (cur | prev) +11 Kosar Doraghi talk contribs | ||||
| N |
|
21:32 (cur | prev) +11,561 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Gepirone |aOrAn=a |drugClass=extended-release tablets |indicationType=treatment |indication=major depressive disorder (MDD) in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, nausea, insomnia, abdominal pain, and dyspepsia |blackBoxWarningTitle=WARNING: SUICIDAL THOUGHTS AND BEHAVIORS |blackBoxWarningBody=SEE FULL PRESCRIBING INFORMATION FOR...") | |||
.jpg){kind=link}
|
|
17:11 | Cryptogenic cirrhosis 6 changes history +3,131 [Imam Ali Shah (6×)] | |||
|
|
17:11 (cur | prev) +8 Imam Ali Shah talk contribs Tag: Visual edit | ||||
|
|
17:03 (cur | prev) +419 Imam Ali Shah talk contribs (Added CT scan images) Tag: Visual edit | ||||
|
|
16:45 (cur | prev) +1,626 Imam Ali Shah talk contribs (Added CT scan images) Tag: Visual edit | ||||
|
|
16:34 (cur | prev) +269 Imam Ali Shah talk contribs Tag: Visual edit | ||||
|
|
16:26 (cur | prev) +476 Imam Ali Shah talk contribs Tag: Visual edit | ||||
|
|
16:21 (cur | prev) +333 Imam Ali Shah talk contribs Tag: Visual edit | ||||
| 16:03 | User:Imam Ali Shah diffhist −61 Imam Ali Shah talk contribs | ||||
| N 14:44 | Template:VSRN diffhist +81 Rithish Nimmagadda talk contribs (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]") | ||||
|
|
N 14:30 | FRUZAQLA 3 changes history +9,129 [Rithish Nimmagadda (3×)] | |||
|
|
14:30 (cur | prev) +2 Rithish Nimmagadda talk contribs Tag: Visual edit | ||||
|
|
14:25 (cur | prev) +35 Rithish Nimmagadda talk contribs | ||||
| N |
|
14:10 (cur | prev) +9,092 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...") | |||
|
|
N 14:21 | User:Rithish Nimmagadda 3 changes history +362 [Rithish Nimmagadda (3×)] | |||
|
|
14:21 (cur | prev) −9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
|
|
14:21 (cur | prev) +9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
| N |
|
14:20 (cur | prev) +362 Rithish Nimmagadda talk contribs (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India") | |||
| N 13:32 | Fruzaqla diffhist +49 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}") | ||||
|
|
04:13 | Zuranolone 2 changes history +5,755 [Alen Antony (2×)] | |||
|
|
04:13 (cur | prev) +2,528 Alen Antony talk contribs | ||||
|
|
03:48 (cur | prev) +3,227 Alen Antony talk contribs | ||||
| 01:58 | User:Edzelco diffhist +22 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| 01:55 | Toripalimab-tpzi diffhist +45,965 Edzelco talk contribs | ||||
7 May 2024
|
|
N 20:18 | Zuranolone 2 changes history +1,853 [Alen Antony (2×)] | |||
|
|
20:18 (cur | prev) +1,017 Alen Antony talk contribs | ||||
| N |
|
17:27 (cur | prev) +836 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...") | |||
|
|
04:14 | User:Archana.vajjala 5 changes history +4 [Archana.vajjala (5×)] | |||
|
|
04:14 (cur | prev) −25 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
04:09 (cur | prev) −40 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:59 (cur | prev) +26 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:56 (cur | prev) +3 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:56 (cur | prev) +40 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
| 03:37 | Perfluorhexyloctane diffhist +904 Alen Antony talk contribs | ||||
6 May 2024
| b 14:43 | User:C Michael Gibson diffhist +187 Meghan Ford talk contribs | ||||
| m 08:50 | Non-degenerate nucleotides per response element diffhist +144 Marshallsumter talk contribs (→Tabulation of counts) | ||||
3 May 2024
| N 22:57 | Xacduro- sulbactam and durlobactam diffhist +11,950 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...") | ||||
|
|
N 19:10 | Perfluorhexyloctane 3 changes history +1,917 [Alen Antony (3×)] | |||
|
|
19:10 (cur | prev) +1,456 Alen Antony talk contribs | ||||
|
|
18:57 (cur | prev) +210 Alen Antony talk contribs | ||||
| N |
|
18:20 (cur | prev) +251 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}") | |||
2 May 2024
| N 15:29 | Trofinetide diffhist +74 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}") | ||||
|
|
N 04:04 | Zavegepant 2 changes history +4,397 [Alen Antony (2×)] | |||
|
|
04:04 (cur | prev) +2,901 Alen Antony talk contribs | ||||
| N |
|
03:29 (cur | prev) +1,496 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...") | |||
|
|
02:13 | Omaveloxolone 4 changes history +3,035 [Alen Antony (4×)] | |||
|
|
02:13 (cur | prev) +439 Alen Antony talk contribs | ||||
|
|
02:10 (cur | prev) +619 Alen Antony talk contribs | ||||
|
|
02:05 (cur | prev) +435 Alen Antony talk contribs | ||||
|
|
01:14 (cur | prev) +1,542 Alen Antony talk contribs | ||||
1 May 2024
|
|
N 23:49 | Omaveloxolone 5 changes history +2,793 [Alen Antony (5×)] | |||
|
|
23:49 (cur | prev) +272 Alen Antony talk contribs | ||||
|
|
23:12 (cur | prev) +836 Alen Antony talk contribs | ||||
|
|
23:02 (cur | prev) +1,322 Alen Antony talk contribs | ||||
|
|
22:20 (cur | prev) +287 Alen Antony talk contribs | ||||
| N |
|
21:51 (cur | prev) +76 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}") | |||
| 18:20 | Electronic medical record diffhist +1,643 Badgettrg talk contribs (→Documentation burden) | ||||
| N 15:46 | Nirsevimab diffhist +15,269 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...") | ||||
|
|
15:31 | (Upload log) [Kosar Doraghi (2×)] | |||
|
|
15:31 Kosar Doraghi talk contribs uploaded File:IMG 1185.jpeg | ||||
|
|
15:29 Kosar Doraghi talk contribs uploaded File:IMG 1187.jpeg | ||||
| 14:19 | User creation log User account Rithish Nimmagadda talk contribs was created by Alberto Castro Molina talk contribs | ||||
| 03:21 | Proteinuria diffhist +997 Badgettrg talk contribs (→Diagnosis) | ||||
30 April 2024
|
|
18:58 | User:AED 4 changes history +85 [Alara E. Dagsali (4×)] | |||
|
|
18:58 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
|
18:47 (cur | prev) +22 Alara E. Dagsali talk contribs | ||||
|
|
18:28 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
|
18:15 (cur | prev) +23 Alara E. Dagsali talk contribs | ||||
|
|
N 18:58 | Isosulfan Blue 2 changes history +5,962 [Alara E. Dagsali (2×)] | |||
|
|
18:58 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:57 (cur | prev) +5,959 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...") | |||
|
|
N 18:47 | Ibuprofen Lysine 2 changes history +15,666 [Alara E. Dagsali (2×)] | |||
|
|
18:47 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:46 (cur | prev) +15,663 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...") | |||
|
|
N 18:28 | Prussian blue 2 changes history +14,070 [Alara E. Dagsali (2×)] | |||
|
|
18:28 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:27 (cur | prev) +14,067 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...") | |||
|
|
N 18:15 | Botulism Antitoxin 2 changes history +18,011 [Alara E. Dagsali (2×)] | |||
|
|
18:15 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:14 (cur | prev) +18,008 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...") | |||
| m 15:35 | Medication reconciliation diffhist +1 Badgettrg talk contribs | ||||
29 April 2024
| 15:26 | User:AED diffhist +27 Alara E. Dagsali talk contribs | ||||
|
|
N 15:25 | Trastuzumab emtansine 2 changes history +40,575 [Alara E. Dagsali (2×)] | |||
|
|
15:25 (cur | prev) −35 Alara E. Dagsali talk contribs | ||||
| N |
|
15:23 (cur | prev) +40,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...") | |||
28 April 2024
| m 06:33 | Non-degenerate nucleotides per response element diffhist +207 Marshallsumter talk contribs (→Tabulation of counts) | ||||
27 April 2024
|
|
m 20:10 | Non-degenerate nucleotides per response element 2 changes history +1,935 [Marshallsumter (2×)] | |||
| m |
|
20:10 (cur | prev) +301 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:46 (cur | prev) +1,634 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 00:49 | Chronic obstructive pulmonary disease history and symptoms diffhist +2,903 Kosar Doraghi talk contribs | ||||
26 April 2024
|
|
m 20:03 | Non-degenerate nucleotides per response element 2 changes history +2,239 [Marshallsumter (2×)] | |||
| m |
|
20:03 (cur | prev) +608 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:34 (cur | prev) +1,631 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:32 | User creation log User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs | ||||
| 04:27 | Daprodustat diffhist +1,079 Alen Antony talk contribs | ||||
25 April 2024
| 22:53 | Reni Syndrome diffhist −3 Alara E. Dagsali talk contribs | ||||
|
|
N 22:52 | User:AED 3 changes history +3,204 [Alara E. Dagsali (3×)] | |||
|
|
22:52 (cur | prev) −144 Alara E. Dagsali talk contribs | ||||
|
|
22:51 (cur | prev) +407 Alara E. Dagsali talk contribs | ||||
| N |
|
22:39 (cur | prev) +2,941 Alara E. Dagsali talk contribs (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...") | |||
| 22:48 | Adagrasib diffhist +3 Alara E. Dagsali talk contribs | ||||
| 22:45 | Norelgestromin diffhist +3 Alara E. Dagsali talk contribs | ||||
|
|
22:45 | Tranexamic 6 changes history +1 [Alara E. Dagsali (6×)] | |||
|
|
22:45 (cur | prev) +11 Alara E. Dagsali talk contribs | ||||
|
|
22:44 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) +2 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
|
22:40 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
22:39 (cur | prev) −14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
| 22:36 | Alara E. Dagsali diffhist +40 Alara E. Dagsali talk contribs | ||||
|
|
N 21:21 | Daprodustat 6 changes history +6,894 [Alen Antony (6×)] | |||
|
|
21:21 (cur | prev) +952 Alen Antony talk contribs | ||||
|
|
20:53 (cur | prev) +1,266 Alen Antony talk contribs | ||||
|
|
19:07 (cur | prev) +2,809 Alen Antony talk contribs | ||||
|
|
17:23 (cur | prev) +563 Alen Antony talk contribs | ||||
|
|
16:47 (cur | prev) +147 Alen Antony talk contribs | ||||
| N |
|
15:23 (cur | prev) +1,157 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...") | |||
| m 17:37 | Non-degenerate nucleotides per response element diffhist +705 Marshallsumter talk contribs (→Tabulation of counts) | ||||
| 17:03 | Chronic hypertension medical therapy diffhist +715 Badgettrg talk contribs (→Impact of Blood Pressure self-monitoring in Hypertension Control) | ||||